Notes
Ce contenu est réservé aux abonnés
Bibliographie
- Petersen, R. C. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379–2388 (2005).
- Doody, R. S. et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 72, 1555–1561 (2009).
- Russ, T. C. & Morling, J. R. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 9, CD009132 (2012).
- Seltzer, B. et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch. Neurol. 61, 1852–1856 (2004).
- Schneider, L. S., Dagerman, K. S., Higgins, J. P. T. & McShane, R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch. Neurol. 68, 991–998 (2011).
- Winblad, B. et al. Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin 25, 2577–2587 (2009).
- Salloway, S. et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology 63, 651–657 (2004).
- Feldman, H. H. et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. The Lancet Neurology 6, 501–512 (2007).
- Winblad, B. et al. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology 70, 2024–2035 (2008).
- Dubois, B. et al. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. Alzheimer's & Dementia 11, 1041–1049 (2015).
Fichiers
-
Fichier du cours pdf
